Antitumor activity and pharmacological properties of furizil
Stukov, A.N.; Kraĭz, B.O.; Aleksandrov, V.A.; Ivin, B.A.; Filov, V.A.
Voprosy Onkologii 31(5): 52-54
1985
ISSN/ISBN: 0507-3758 PMID: 4013130 Document Number: 250797
The paper discusses the biological properties of 2-(2-furyl)-5-oxymethyl-5-(2,4-diethylenimino-1,3,5-trazin-6-yl)amino-1,3-dioxane (furisyl), synthesized by substituting ethyleniminic groups for chlorine atoms in individual stereoisomer of a dichlortriazin derivative. Furisyl was found to inhibit the growth of Ehrlich's tumor, Walker's carcinosarcoma, sarcoma 45 and rat ovarian tumors, the inhibition rate ranging 76-100%. Parenterally administered, LD50 appeared to be 6 mg/kg for rats and 15 mg/kg for mice. Studies of chronic toxicity established damaging effects of furisyl on hematopoietic gastrointestinal and reproductive organs. Toxic effects subsided 1-2 weeks after the drug withdrawal.